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Injection sclerotherapy is widely used in the treatment of oesophageal varices. However, few studies
have compared the local toxicity of sclerosant agents which may be important if serious local complica-
tions are to be avoided.
In this study the depth of injury caused by submucosal injection of increasing concentrations of
sodium tetradecyl sulphate, polidocanol, 5% ethanolamine oleate and 5% varicosid in rabbits stomach,
has been compared by histopathological examination.
Macroscopic ulceration was seen in 14.6% of injection sites. Increasing concentrations of sodium
tetradecyl sulphate and polidocanol produced increasingly extensive microscopic inflammation. Five
percent varicosid caused more inflammation than 5% ethanolamine and only 3% polidocanol and 5%
varicosid caused full thickness inflammation. Only 5% ethanolamine produced inflammation consis-
tently confined to the mucosa and submucosa.
On the basis of this study we feel that 5% ethanolamine is the most suitable agent for injection
sclerotherapy.
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INTRODUCTION
Endoscopic injection sclerotherapy has a well established place in the management
of acute variceal haemorrhage and in the more long-term treatment of oesophageal
varices1’2’3. However, the local effects of sclerosant agents are the least well studied
area of variceal sclerotherapy. Whilst there is some evidence that intravascular
injection is more effective than the paravariceal technique4, some submucosal ex-
travasation can be expected even with intravariceal injection and this probably
accounts for the significant incidence of local ulceration seen5. Few studies have
compared the local inflammatory response to sclerosant agents and there is little
scientific basis on which to choose the best sclerosant. The local toxicity of several
commonly used sclerosants has been compared in this study in which the depth
and severity of inflammation caused by sclerosant injection in rabbits stomach has
been assessed by histopathological examination.
METHOD
Twenty rabbits underwent laparotomy and gastrotomy under general anaesthesia
(Hypnorm [Janssen Ltd] 0.25 ml/kg I.M. + N20/02/Halothane). Each rabbit
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received 3 submucosal injections of sclerosant at different sites within upper
stomach. The injection sites were marked by indentifiable, non-absorbable sutures.
Four groups were studied: Group A (n= 10) received 0.1 ml of 1%, 2% and 3%
sodium tetradecyl sulphate (STD) at one of the 3 injection sites; Group B (n= 5)
received 0.1 ml of 5% ethanolamine oleate (EO) at each of the 3 injections sites.
Group C (n=5) received 0.1 ml of 0.5%, 2% and 3% polidocanol at 1 of 3 injection
sites. Group D (n=5) received 0.1 ml of 5% varicosid (sodium morrhuate) at each
of the 3 injection sites. 0.1 ml was the chosen volume of sclerosant per injection
site in the. rabbit because it is approximately the ratio of sclerosant to body weight
used in patients (eg 0.05 ml/kg body weight). Injections were judged to be into the
submucosa when an easily identifiable submucosal bleb was raised.
The gastrotomy was closed and the rabbits recovered. One week following injec-
tion the rabbits were sacrificed and the stomach removed for histopathological
examination. Representative blocks were cut from each of the marked injection
sites and in addition control blocks were taken from areas of the stomach in-
between injection sites.
Standard haematoxylin and eosin stained sections were prepared and examined
by one histopathologist, who was unaware of the sclerosant used. To assess the
degree of local tissue reaction sections were scored according to the depth of in-
flammation present on a scale of 1-4 (Table 1).
Statistical Analysis was by Fisher’s Exact Test and a value of p < 0.05 was taken
to denote statistical significance.
Table 1 Pathologists score of the depth of inflammation at the injection site







Full thickness of stomach wall/perforation
RESULTS
Whilst all injection sites appeared inflammed to the naked eye, macroscopic ulcer-
ation was only seen in 11 of the 75 injection sites (14.6%).
The results of histopathological examination are summarised in Table 2. Col-
lapsing the data, by combining groups 1 with 2 and 3 with 4, allowed statistical
analysis using Fisher’s Exact Test. The depth of injury increased with increasing
concentrations of S.T.D. (1% v 2% p < 0.01, 1% v 3% p < 0.01, 2% v 3% p <
0.01) andpolidocanol(0.5% v2% p NS;2% v3% p NS;0.5% v3% p<
0.01) but only one of the 3% polidocanol injection sites showed full thickness in-
flammation. 5% varicosid caused more inflammation than 5% ethanolamine oleate
and none of the E.O. injection sites showed inflammation of the muscularis propria
in contrast one of the 5% varicosid injection sites showed full thickness
inflammation.
Control blocks showed only an organising peritoneal reaction consistent with a
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Table 2 Summary of histopathological findings.
Macroscopic
ulceration
Depth of inflammation at injection sites
Groups 2 3 4
A STD
(n 10)
1% 0 5 5 0 0
2% 0 4 5 0
3% 4 0 0 10 0
B 5% Ethanolamine
(n 5) oleate
0 0 15 0 0
C Polidocanol
(n 5) 0.5% 0 4 0 0
2% 1 0 3 2 0





3 0 4 10
v 1% STD p NS
v 2% STD p < 0.01
v 3% STD p < 0.01
v 0.5% Polidocanol p NS
v 2% Polidocanol p < 0.05
v 3% Polidocanol p < 0.01
v 5% Variscosid p <0.01
DISCUSSION
The choice of sclerosant used for variceal injection sclerotherapy varies in different
countries and different units but in the UK STD and EO are the 2 most frequently
used, whereas in other parts of Europe hydroxypolyethoxy dodecanoic acid
(Polidocanol) and varicosid (sodium morrhuate) are commonly used.
A rational choice of sclerosant would take into account its efficacy, local toxicity,
ease of injection and systemic effects eg anaphylaxis and fever. Ideally a sclerosant
would cause thrombosis of the varix with few local complications. Ulceration,
stricture formation and, rarely, perforation are local complications thought to be
the direct result of the intensity of local inflammation. Some authors6 recommend
paravasal, submucosal injections of sclerosant to achieve oesophageal wall
sclerosis, thus burying the varices in a thick protective fibrous coat. This technique
may lead to more local complications and in addition during intended intravariceal
injection some extravasation is likely to occur7. We therefore felt it was worthwhile
to try and identify the degree of local inflammation caused by different sclerosants.
Whilst we are aware that gastric mucosa is not identical to oesophageal mucosa,
we were specifically interested in the local tissue damage caused by the sclerosants.
Ulceration may occur over a variable time period but we felt that serial analysis
would have required the sacrifice of large numbers of rabbits.
Macroscopic ulceration was only seen in 14.6% of our injection sites however it
has been claimed that oesophageal ulceration is a necessary accompaniment rather
than an unavoidable complication of sclerotherapy5. Both 3% polidocanol and 5%
varicosid caused inflammation of the muscle layer and full thickness inflammation.152 C.S. ROBERTSON et al.
This is probably undesirable as it may contribute to the small but very real risk of
oesophageal stricture formation following injection sclerotherapy8. In a study of
the effect of sclerosants using rat femoral vein9, Blenkinsop has shown that 1 and
3% STD were superior to EO whilst STD and EO were equally ulcerogenic when
injected subcutaneously. Silpa et al. found in a study of efficacy and safety of
sclerosing agents that STD was effective but there was a 60% incidence of
oesophageal ulceration1.
Gibbert et al. in another comparative study of sclerosants found 3% S.T.D. to
be associated with less oesophageal ulceration than sodium morrhuate11. STD is
less viscous than EO and therefore more easily injected and it is also less irritant
to the eye if spillage occurs while injecting under high pressure12. In addition, STD
may have a more marked effect on increasing blood viscosity than EO13. However,
only 5% E.O. injection sites consistently produced inflammation confined to the
mucosa and submucosa and we therefore feel that it is the most suitable agent for
injection sclerotherapy of oesophageal varices.
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INVITED COMMENTARY
Endoscopic sclerotherapy is now established as the "best buy" in the management
of the acute bleeding episode from oesophageal varices. A programme of chronic
injection sclerotherapy is also effective in reducing the risk of recurrent haemor-
rhage. However many points of sclerotherapy technique remain controversial: the
use of anaesthesia or sedation, flexible or rigid instrument, intra- or para-variceal
injection, compression or not, site of injection, ideal treatment intervals and the
best sclerosant. This paper by Robertson and colleagues deals with this last point.
There is a wide variety of sclerosants in current use and this aspect of
management has received remarkably little investigation. In the case of in-
travariceal injections the ideal sclerosant would be one which causes variceal
thrombosis with minimal inflammation of the surrounding tissue. However realis-
tically even those who attempt intravascular injection acknowledge that sclerosant
goes outside the vein in about 20 per cent of instances in the case of large varices
and in a much higher percentage of patients with small varices1. Where paravariceal
injection is preferred the ideal sclerosant should cause sufficient inflammation to
cause thickening and fibrosis of the mucosa with a view to protecting the underlying
varices. Some centres consider superficial ulceration of the mucosa of the lower
oesophagus to be desirable and an end point to sclerotherapy2’3. I am unhappy
with this viewpoint since ulceration carries not only the risk of further bleeding
but also subsequent oesophageal stricture secondary to fibrosis. More and more
centres are now reporting a significant incidence of oesophageal strictures after
courses of sderotherapy.
There are a number of sclerosants in common use. Sodium tetradecyl sulphate
(STD) is widely used in the USA. Polidocanol is the favoured agent in Europe.
Absolute alcohol is used in India and is claimed to be both economical and
effective. Ethanolamine oleate (EO) is at present the most commonly used
sclerosant in the British Isles, Japan and South Africa. This paper by Robertson
and colleagues is useful in assessing the relative merits of the most commonly used
agents. Although the study is experimental and used submucosal injections in the
rabbits’ stomachs, the results are probably relevant to the clinical situation. Their
experimental work however cannot allow the authors to conclude that EO "is the
most suitable agent for injection sclerotherapy of oesophageal varices." They do
show that it gives less serious inflammation and is therefore less likely to produce
perforation, ulceration or stricture but this experimental study cannot demonstrate
that the agent is effective in reducing bleeding from oesophageal varices. In
another animal experiment Jansen and colleagues found EO and STD to be
similarly effective in producing thrombosis but the ulceration rate with STD was
much higher, namely, 40 per cent4. In a recent controlled trial involving 45 patients
with cirrhosis Kitano and colleagues showed that EO was both safer and more
effective and 2 per cent STD for intravariceal injection3. There was significantly
less post-injection bleeding with EO and the incidence of oesophageal ulceration
was only nine per cent compared to 43 per cent with STD. They used the in-
travariceal route of injection and a number of trials suggest it is the more effective
route1’5. Nevertheless the results obtained by Paquet using the paravariceal route
are among the best in the world6. We have been using intravariceal EO for
injection sclerotherapy in Belfast for thirty years7. More than 400 patients have
had in excess of 800 episodes of injection sclerotherapy. We do not154 C.S. ROBERTSON et al.
have a true figure for the incidence of oesophageal ulceration since we tend to do
the injections at monthly intervals and therefore rarely see ulceration. However
we can say that in the whole period no patient with cirrhosis developed a
symptomatic oesophageal stricture. Two patients with extrahepatic block, each re-
ceiving more than 12 episodes of sclerotherapy, developed strictures- both were
relieved with only one dilatation.
From the evidence currently available we feel that the intravariceal injection of
EO is probably the "best buy" where injection sclerotherapy is used for the control
of bleeding oesophageal varices.
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